Patents by Inventor David Witter

David Witter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090069250
    Abstract: The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
    Type: Application
    Filed: February 23, 2007
    Publication date: March 12, 2009
    Inventors: Jonathan B. Grimm, Jed L. Hubbs, Thomas Miller, Karin M. Otte, Phieng Siliphaivanh, Matthew G. Stanton, Kevin Wilson, David Witter, Hua Zhou
  • Publication number: 20080096920
    Abstract: This invention relates to iminodiacetic acid and diamine hydroxamic acid derivatives, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Application
    Filed: July 15, 2005
    Publication date: April 24, 2008
    Inventors: Sandro Belvedere, Thomas Miller, David Witter
  • Publication number: 20080070936
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Application
    Filed: September 20, 2007
    Publication date: March 20, 2008
    Inventors: Arlindo Castelhano, Bryan McKibben, David Witter
  • Publication number: 20080033015
    Abstract: This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Application
    Filed: July 8, 2005
    Publication date: February 7, 2008
    Inventors: Sandro Belvedere, Christopher Hamblett, Thomas Miller, David Witter, Jiaming Yan
  • Publication number: 20080015216
    Abstract: This invention relates to hydroxamic acid derivatives having a sulfonamide linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, autoimmune, allergic and inflammatory diseases, diseases of the central nervous system (CNS) such as neurodegenerative diseases, and in the prevention and/or treatment of restenosis.
    Type: Application
    Filed: July 8, 2005
    Publication date: January 17, 2008
    Inventors: Sandro Belvedere, Joey Lee Methot, Thomas Miller, David Witter, Jiaming Yan
  • Publication number: 20070213392
    Abstract: The present invention relates to a novel class of hydroxamic acid derivatives having a benzothiophene or thiophene backbone. The hydroxamic acid compounds can be used to treat cancer. The hydroxamic acid compounds can also inhibit historic deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention are also useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.
    Type: Application
    Filed: October 8, 2004
    Publication date: September 13, 2007
    Inventors: Thomas Miller, David Witter, Sandro Belvedere
  • Patent number: 7262196
    Abstract: Compounds of Formula (I): or pharmaceutically acceptable salts or N-oxides thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.
    Type: Grant
    Filed: February 10, 2004
    Date of Patent: August 28, 2007
    Assignee: Prosidion Limited
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, Maseo Nawano, Martin James Procter, Chrystelle Marie Rasamison, Geoffrey Martyn Williams, David Witter, Arlindo Castelhano, Kosuke Yasuda
  • Patent number: 7064122
    Abstract: The subject invention features compounds having the structure: wherein X is O, S, CH2 or NR5; Y is O or S; R1 is H, substituted or unsubstituted C1-C15 alkyl, C1-C8 alkylaryl, —C(O)OR4, —C(O)NR4R5, —CR6R6?OR4, —CR6R6?OC(O)R4, —CR6R6?OC(O)NHR7, —C(O)NR10R11, —C(O)NR8R9NR8R9, —N(R5)C(O)NHR5, or CH2R4; R2 is a substituted or unsubstituted, straight chain C1—C30 alkyl or branched C3-C30 alkyl, aryl, alkylaryl, arylalkyl, heteroarylalkyl or cycloalkyl; R3 is H or substituted or unsubstituted C1-C6 alkyl or C3-C10 cycloalkyl; R4 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl, —CH2-aryl, aryl —C1-C15 alkyl, heteroaryl-C1-C15alkyl or C3-C10 cycloalkyl; R5 is H or a substituted or unsubstituted, straight chain or branched, C6-C30 alkyl, aryl C1-C30alkyl, heteroarylalkyl or cycloalkyl; R6 and R6? are each independently H, substituted or unsubstituted C1-C6 alkyl, dialkyl or C3-C10 cycloalkyl or together form a 3-7 membered ring system; R7 is H or substituted or unsubstituted
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: June 20, 2006
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: David Witter, Arlindo Castelhano
  • Publication number: 20050090513
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 and A3 receptors and the use of these compounds to treat a disease associated with A3 adenosine receptor in a subject, comprising administering to the subject a therapeutically effective amount of the compounds.
    Type: Application
    Filed: November 27, 2002
    Publication date: April 28, 2005
    Inventors: Arlindo Castelhano, Bryan McKibben, Douglas Werner, David Witter
  • Publication number: 20050043332
    Abstract: Novel deazapurines are disclosed which are useful for the treatment of adenosine receptor stimulated diseases.
    Type: Application
    Filed: March 31, 2004
    Publication date: February 24, 2005
    Inventors: Arlindo Castelhano, Bryan McKibben, David Witter
  • Publication number: 20040186290
    Abstract: Compounds of Formula (I): 1
    Type: Application
    Filed: February 10, 2004
    Publication date: September 23, 2004
    Inventors: Matthew Colin Thor Fyfe, Lisa Sarah Gardner, Maseo Nawano, Martin James Procter, Chrystelle Marie Rasamison, Geoffrey Martyn Williams, David Witter, Arlindo Castelhano, Kosuke Yasuda
  • Publication number: 20030195199
    Abstract: The subject invention features compounds having the structure: 1
    Type: Application
    Filed: December 20, 2002
    Publication date: October 16, 2003
    Inventors: David Witter, Arlindo Castelhano